No Data
No Data
Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $16 price target.
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals Amends Global Trial and Equity Terms
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement With Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market
Verrica Pharmaceuticals Shares Are Trading Higher Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. Also, Needham and HC Wainwright Raised Their Respective Price...
Verrica Pharmaceuticals Shares Are Trading Higher Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. Also, Needham an
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Roth MKM cu
No Data